In previous studies, PDGFRB immunostaining was used to assess microvasculature, showing a reduction of PDGFRB‐positive pericytes and a breakdown of the blood‐brain barrier in vascular cognitive impairment and some neurodegenerative diseases, including AD and ALS 46, 51, 55, 56, 59. This evidence concerns the gene PDGFRB and neurodegenerative disease.